Endo License and Development Agreement - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended	12 Months Ended								9 Months Ended
	Sep. 30, 2014 Milestone	Dec. 31, 2013	Dec. 31, 2012	Jun. 25, 2014	Jan. 23, 2014	May 31, 2012	Jan. 17, 2012	Jan. 31, 2014 Clinical Trials One [Member]	Jun. 30, 2014 Clinical Trials Two [Member]	Sep. 30, 2014 Endo License and Development Agreement [Member]
Related Party Transaction [Line Items]
Non-refundable payment received							$ 30
Potential milestone payments on intellectual property rights	15
Potential milestone payment received clinical development	20							10	10
Potential payment upon filing and acceptance	10.0
Potential milestone payment receivable upon regulatory approval	50
Payment receivable on achievement of potential sales milestones	55
Number of potential sales milestones	4
Recognized up-front payment allocated to the license	15.6
Recognized up-front payment to clinical trial material and development services	14.4
Upfront payment	30
Estimated amount recognized against clinical services deliverable	2.3	6.3	5.2
Deferred revenue income of the research and development activities	0.6									12.1
Term of Endo Agreement	10 years
Extended patent on drug delivery technology	2020 to 2027
Potential milestone payments on issuance of patent						15
Milestone payment regarding licensing agreement				10	10
Total rate of reimbursable contractor costs borne	50.00%									50.00%
Reimbursement rate of costs by Endo to the company as per agreement										100.00%
Percentage of credit against potential future milestone										50.00%
Deferred revenue recognized during the period	$ 4.8